David Hipkiss, Executive Chair of AlveoGene had the great pleasure of talking with Amy Brown of BioTech TV at BioTrinity 2025 in London and outlines how we are using our InGenuiTy® inhaled gene therapy platform to deliver transformational outcomes in rare respiratory disease.
Click here for the full interview (11 mins)
